pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ALNYALNYLAM PHARMACEUTICALS, INC.

$ALNY159.73-3.22%
Cambridge, MA, USupdated 14h ago

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
6
marketed
4
phase 3
2
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(6)

pipeline depth6 products
Phase 3: 2Marketed: 4
2Phase 34Marketed
Marketed
givosiran
Acute Intermittent Porphyria
Marketed
lumasiran
Primary Hyperoxaluria Type I
Marketed
patisiran
Familial Amyloid Neuropathies
Marketed
vutrisiran
Familial Amyloid Cardiomyopathy
Phase 3
nucresiran
Familial Amyloid Cardiomyopathy
Phase 3
zilebesiran sodium
Hypertension

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Oct 29, 2026
earnings
$ALNY159.73-3.22%
19d ago
ALNYLAM PHARMACEUTICALS, INC. earnings
ALNYLAM PHARMACEUTICALS, INC.
→
view all catalysts →

Active trials

  • phase1A Study to Evaluate ALN-4285 in Adult Healthy Volunteersrecruitingn=76
  • phase2A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathyactive not recruitingn=210
  • phase2HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMBrecruitingn=24
  • phase2A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMactive not recruitingn=105
  • phase1A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Diseaserecruitingn=66
  • phase3Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Diseaserecruitingn=11,000
  • phase1A Study to Evaluate ALN-5288 in Patients With Alzheimer's Diseaserecruitingn=50
  • —Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Programrecruitingn=10
🐶 Hiring Signal
No open roles indexed yet — view ALNYLAM PHARMACEUTICALS, INC. jobs →

News

  • Blackstone bets $1.5B on Pfizer’s obesity drug
    The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
    biopharma_dive · 4d ago
  • Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
    The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
    biopharma_dive · 10d ago
  • Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
    RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study in 2027 once regulatory alignment is achieved.
    biospace · 24d ago
  • City goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq
    City Therapeutics has gone public with an upsized $200 million IPO, on the same day that Frazier Life Sciences listed its second biotech-focused shell company.
    fiercebiotech · 1mo ago
  • Roche expands obesity R&D footprint with Rona deal worth $1B+
    Roche has gained access to a genetic obesity approach from China's Rona Therapeutics for up to $100 million in upfront and near-term payments.
    biospace · 1mo ago
  • The top biopharma conferences in 2027
    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.
    biopharma_dive · 1mo ago
  • ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’
    Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.
    biopharma_dive · 1mo ago
  • ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
    ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.
    fiercebiotech · 1mo ago
  • ‘Worse than expected’ Wainua data muddies water for TTR silencers
    AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined with the…
    biospace · 2mo ago
  • STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
    AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a competitive billion-dollar market.
    stat · 2mo ago
view all news mentions →
identifiers
ticker
$ALNY
SEC CIK
0001178670
country
US
source
sec_tickers
top tags
Cardiology1Hypertension1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 58m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?